These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9350248)

  • 1. [Cardiotoxicity due to prolonged administration of THP (2"R-4'-O-tetrahydropyranyl-adriamycin)].
    Suzuki M; Hirono M; Majima H
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1993-9. PubMed ID: 9350248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preliminary phase II clinical study of 4'-O-tetrahydropyranyl doxorubicin (THP-ADM)].
    Majima H
    Gan To Kagaku Ryoho; 1983 Mar; 10(3):805-10. PubMed ID: 6882000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase II study of 4'-O-tetrahydropyranyl-adriamycin (THP-ADM) in patients with gynecological cancer].
    Kato T; Nishimura H; Umezu J; Takeuchi S; Kanazawa K; Inoue H; Suzuki M; Hirono M; Suzuki T; Okajima H
    Gan To Kagaku Ryoho; 1985 Oct; 12(10):1962-7. PubMed ID: 4051511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
    Uyar D; Kulp B; Peterson G; Zanotti K; Markman M; Belinson J
    Gynecol Oncol; 2004 Jul; 94(1):147-51. PubMed ID: 15262133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acute cardiotoxicity of anthracyclines--analysis by using Holter ECG].
    Okuma K; Furuta I; Ota K
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):902-11. PubMed ID: 6202243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase II study of 4'-O-tetrahydropyranyladriamycin(THP-ADM)].
    Nakada H; Ogawa M; Miyamoto H; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Usui N; Adachi K; Okada Y
    Gan To Kagaku Ryoho; 1984 Jan; 11(1):138-42. PubMed ID: 6696455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Electrocardiogram analysis of adriamycin cardiotoxicity in 160 cases].
    Wang SQ
    Zhonghua Zhong Liu Za Zhi; 1991 Jan; 13(1):71-3. PubMed ID: 1889343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adriamycin cardiac toxicity: a different hypothesis.
    Byfield JE
    Cancer Treat Rep; 1977; 61(3):497-8. PubMed ID: 872149
    [No Abstract]   [Full Text] [Related]  

  • 10. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
    Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Postoperative prophylactic intravesical instillation of tetrahydropyranyl-adriamycin (THP) for superficial bladder cancer].
    Kanayama H; Yokota K; Kurokawa Y; Kagawa S; Yokozeki H; Inai T; Ogawa I; Akazawa S; Hashimoto H; Mizuta K
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):651-5. PubMed ID: 10234296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin.
    Villani F; Galimberti M; Comazzi R; Crippa F; Bonfante V; Ferrari L; Pacciarini MA
    Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):185-9. PubMed ID: 3403095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a 1-hour IV infusion of doxorubicin on the development of cardiotoxicity in dogs as evaluated by electrocardiography and echocardiography.
    Gillings S; Johnson J; Fulmer A; Hauck M
    Vet Ther; 2009; 10(1-2):46-58. PubMed ID: 19742448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preoperative intra-arterial chemotherapy with THP-ADR for locally advanced breast cancer].
    Mukai S; Fujisaki T; Sato N
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1542-5. PubMed ID: 7574754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia.
    Shimomura Y; Baba R; Watanabe A; Horikoshi Y; Asami K; Hyakuna N; Iwai A; Matsushita T; Yamaji K; Hori T; Tsurusawa M;
    Pediatr Blood Cancer; 2011 Sep; 57(3):461-6. PubMed ID: 21298773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton G; Blessing J; Hanjani P; Kramer P;
    Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
    Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
    Fokkema E; Verweij J; van Oosterom AT; Uges DR; Spinelli R; Valota O; de Vries EG; Groen HJ
    Br J Cancer; 2000 Feb; 82(4):767-71. PubMed ID: 10732743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of acute cardiotoxicity of anti-cancer agents-- analysis using Holter ECG monitoring].
    Okuma K; Ariyoshi Y; Ota K
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1893-900. PubMed ID: 3164181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.